Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361373 | 0.97 | HPGD (0.37) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL44111 | 0.97 | HPGD (0.37) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL5051961 | 0.93 | HDAC1 (0.33) | HDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL12056750 | 0.92 | HPGD (0.36) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL18306340 | 0.91 | HPGD (0.36) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL29486520 | 0.90 | HPGD (0.35) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL31005444 | 0.90 | HPGD (0.42) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL43173 | 0.90 | HPGD (0.42) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL29355223 | 0.90 | HPGD (0.42) | HPGDHDAC1HDAC2HDAC4HDAC6 | |
| SCHEMBL2283058 | 0.89 | HPGD (0.46) | HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590176-B2 | Engineered programmable molecular scaffolds from porous protein crystals | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170362282-A1 | ENGINEERED PROGRAMMABLE MOLECULAR SCAFFOLDS FROM POROUS PROTEIN CRYSTALS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362282-A1 | ENGINEERED PROGRAMMABLE MOLECULAR SCAFFOLDS FROM POROUS PROTEIN CRYSTALS | CRYAA, MAX, CRYAB | HPGD 3307/4885HDAC1 4426/4885HDAC2 4626/4885 |
| US-10590176-B2 | Engineered programmable molecular scaffolds from porous protein crystals | CRYAA, MAX, CRYAB | HPGD 3307/4885HDAC1 4426/4885HDAC2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.